Company intelligence / Profile preview
Sareum Holdings Plc
Cambridge, United Kingdomsareum.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 1
01
Overview
Sareum is developing next-generation kinase inhibitors for autoimmune diseases and cancer. Their lead program SDC-1801 targets TYK2/JAK1 for autoimmune diseases, particularly psoriasis. They also have SDC-1802 for cancer and hold economic interest in SRA737, a Chk1 inhibitor in clinical trials for advanced cancers.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Small moleculesKinase inhibitors
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Sareum Holdings Plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sareum Holdings Plc.